FDA grants orphan drug status to Bayer's bronchiectasis medicine Ciprofloxacin DPI
The US Food and Drug Administration (FDA) has granted orphan drug designation for Bayer HealthCare's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) to treat patients with non-cystic fibrosis bronchiectasis (NCFB).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Cipro | Ciprofloxacin | Cystic Fibrosis | Food and Drug Administration (FDA) | Grants | Pharmaceuticals